Loading asset research
Hemab Therapeutics Holdings Inc. Common Stock
COAGNasdaq · USD · StocksQuote as of · Exchange session not verified$41.32
+0.85%
Today
COAG
Loading 1D prices…
Market cap
$1.9B
Volume
429K
52w high
$55.4252w low
$23.00Company profile
Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
59
Fiscal year end
1231
CIK
2114044
Session & valuation
Open$41.23
Previous close$40.97
Day high$43.47
Day low$40.42
30-day avg. volume342.2K
Outstanding shares46.7M
Diluted EPS-$2.33
Latest annual period
P/E (trailing)-17.73
P/E (forward)-16.24
Price / book4.24
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MESOMesoblast Limited American Depositary Shares | $1.9B | $120.3M | -47.82% | -$0.846 | +3.26% | Buy |
| ALVOAlvotech Ordinary Shares | $1.9B | $586.3M | +4.76% | $0.10 | +4.71% | Hold |
| RXRXRecursion Pharmaceuticals Inc. Class A Common Stock | $1.9B | $74.7M | -863.35% | -$1.44 | +11.13% | Hold |
| ADMAADMA Biologics Inc Common Stock | $2B | $510.2M | +28.80% | $0.60 | +0.73% | Buy |
| VIRVir Biotechnology Inc. Common Stock | $1.8B | $68.6M | -638.87% | -$3.16 | +3.80% | Buy |